Asthma is a common respiratory disease among both adults and children and short acting inhaled beta-2 agonists are used widely for 'reliever' bronchodilator therapy. Long acting beta-2 agonists (LABA) were introduced as prospective 'symptom controllers' in addition to inhaled corticosteroid 'preventer' therapy (ICS).
We originally analysed studies comparing the use of LABA with placebo in mixed populations in which only some were taking ICS and in populations not using ICS therapy. However international guidelines no longer recommend the use of LABA in people who are not taking ICS for their asthma. We are therefore no longer updating this review.